Tech Company Financing Transactions
Grove Biopharma Funding Round
Grove Biopharma, operating out of Chicago, raised $30 million in investment from DCVC Bio, Eli Lilly and Company and Gradiant.
Transaction Overview
Company Name
Announced On
4/24/2025
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to further advance its platform and drive its lead oncology programs towards the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1375 West Fulton Street
Chicago, IL 60607
USA
Chicago, IL 60607
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Grove is a multidisciplinary team of chemists, biologists, materials scientists, and entrepreneurs working together to advance a new synthetic drug modality with transformative potential for patients. Our novel Bionic Biologics� platform integrates principles of biologic and synthetic design. This innovative platform enables the targeting of well-validated yet previously intractable disease drivers, unlocking new possibilities for therapeutic intervention.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Geoffrey Duyk
Chief Operating Officer
Laura Robinson
President
Paul Bertin
VP - Sales
Robert Campbell
Browse more venture capital transactions:
Prev: 4/24/2025: Ravenna venture capital transaction
Next: 4/24/2025: ChEmpower venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs